Related Experiment Video
Updated: Dec 23, 2025
Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
KLF2 inhibits TGF-β-mediated cancer cell motility in hepatocellular carcinoma
Yining Li1, Shuo Tu1, Yi Zeng1
1Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Nanchang University, Nanchang 330006, China.
Abstract:
Feedback regulation plays a pivotal role in determining the intensity and duration of TGF-β signaling and subsequently affecting the pathophysiological roles of TGF-β, including those in liver malignancy. KLF2, a member of the Krüppel-like factor (KLF) family transcription factors, has been implicated in impeding hepatocellular carcinoma (HCC) development. However, the underlying molecular mechanisms are not fully understood. In the present study, we found that TGF-β stimulates the expression of KLF2 gene in several HCC cell lines. KLF2 protein is able to inhibit TGF-β/Smad signaling in HCC cells as assessed by luciferase reporter assay. Further studies indicated that KLF2 inhibits the transcriptional activity of Smad2/3 and Smad4 and ameliorates TGF-β-induced target gene expression, therefore creating a novel negative feedback loop in TGF-β signaling. Functionally, stably expression of KLF2 in HCCLM3 cells attenuated TGF-β-induced cancer cell motility in wound-healing and transwell assays by interfering with TGF-β-mediated upregulation of MMP2. Together, our results revealed that KLF2 protein has a tumor-suppressive function in HCC through a negative feedback loop over TGF-β signaling.
Insights
Krüppel-like factor 2 (KLF2) impedes liver cancer by creating a negative feedback loop in transforming growth factor-beta (TGF-β) signaling. KLF2 inhibits TGF-β/Smad pathways, reducing hepatocellular carcinoma cell motility and tumor growth.
Area of Science:
- Molecular Biology
- Cancer Research
- Cell Signaling
Background:
- Transforming growth factor-beta (TGF-β) signaling is crucial in liver pathophysiology, including liver malignancy.
- Krüppel-like factor 2 (KLF2) is known to inhibit hepatocellular carcinoma (HCC) development, but its mechanism is unclear.
Purpose of the Study:
- To elucidate the molecular mechanisms by which KLF2 influences TGF-β signaling in HCC.
- To investigate the role of KLF2 as a negative regulator of TGF-β signaling in liver cancer.
Main Methods:
- Luciferase reporter assays to assess KLF2's inhibition of TGF-β/Smad signaling.
- Analysis of KLF2's effect on Smad2/3 and Smad4 transcriptional activity.
- Wound-healing and transwell assays to evaluate cancer cell motility.
- Examination of MMP2 expression in response to TGF-β and KLF2.
Main Results:
- TGF-β stimulation increases KLF2 gene expression in HCC cell lines.
- KLF2 protein inhibits TGF-β/Smad signaling by suppressing Smad2/3 and Smad4 activity.
- KLF2 ameliorates TGF-β-induced target gene expression, establishing a negative feedback loop.
- KLF2 expression attenuates TGF-β-induced cancer cell motility and MMP2 upregulation.
Conclusions:
- KLF2 acts as a tumor suppressor in HCC by establishing a novel negative feedback loop in TGF-β signaling.
- KLF2 inhibits hepatocellular carcinoma progression by modulating TGF-β-mediated pathways and cell motility.
More Related Videos
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
12:24A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
Related Concept Videos
01:16TGF - β Signaling Pathway
02:38Mitogens and the Cell Cycle